Your browser doesn't support javascript.
loading
Hemodynamic Performances and Clinical Outcomes in Patients Undergoing Valve-in-Valve Versus Native Transcatheter Aortic Valve Implantation.
Akodad, Mariama; Meilhac, Alexandra; Lefèvre, Thierry; Cayla, Guillaume; Lattuca, Benoit; Autissier, Cécile; Duflos, Claire; Gandet, Thomas; Macia, Jean-Christophe; Delseny, Delphine; Roubille, Francois; Maupas, Eric; Schmutz, Laurent; Piot, Christophe; Targosz, Frédéric; Robert, Gabriel; Rivalland, François; Albat, Bernard; Chevalier, Bernard; Leclercq, Florence.
Afiliação
  • Akodad M; Department of Cardiology, Montpellier University hospital, Montpellier University, France; PhyMedExp, University of Montpellier, Montpellier, France.
  • Meilhac A; Department of Cardiology, Montpellier University hospital, Montpellier University, France.
  • Lefèvre T; Department of Interventional Cardiology, Hôpital Privé Jacques Cartier, Massy, France.
  • Cayla G; Department of Cardiology, Nîmes University hospital, Montpellier University, France.
  • Lattuca B; Department of Cardiology, Nîmes University hospital, Montpellier University, France.
  • Autissier C; Department of Medical Information, Montpellier University hospital, Montpellier University, France.
  • Duflos C; Department of Medical Information, Montpellier University hospital, Montpellier University, France.
  • Gandet T; Department of Cardiovascular Surgery, Montpellier University hospital, Montpellier University, France.
  • Macia JC; Department of Cardiology, Montpellier University hospital, Montpellier University, France.
  • Delseny D; Department of Cardiology, Montpellier University hospital, Montpellier University, France.
  • Roubille F; Department of Cardiology, Montpellier University hospital, Montpellier University, France; PhyMedExp, University of Montpellier, Montpellier, France.
  • Maupas E; Department of Cardiology, Clinique des Franciscaines, Nîmes, France.
  • Schmutz L; Department of Cardiology, Nîmes University hospital, Montpellier University, France.
  • Piot C; Department of Cardiology, Clinique du Millénaire, Montpellier, France.
  • Targosz F; Department of Cardiology, Perpignan hospital, France.
  • Robert G; Department of Cardiology, Clinique Saint Pierre, Perpignan, France.
  • Rivalland F; Department of Cardiology, Clinique du Parc, Montpellier, France.
  • Albat B; Department of Cardiovascular Surgery, Montpellier University hospital, Montpellier University, France.
  • Chevalier B; Department of Interventional Cardiology, Hôpital Privé Jacques Cartier, Massy, France.
  • Leclercq F; Department of Cardiology, Montpellier University hospital, Montpellier University, France; PhyMedExp, University of Montpellier, Montpellier, France. Electronic address: leclercq.florence@club-internet.fr.
Am J Cardiol ; 124(1): 90-97, 2019 07 01.
Article em En | MEDLINE | ID: mdl-31076081
ABSTRACT
Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) emerged has a less invasive treatment than surgery for patients with degenerated bioprosthesis. However, few data are currently available regarding results of ViV versus TAVI in native aortic valve. We aimed to compare hemodynamic performances and 1-year outcomes between patients who underwent ViV procedure and patients who underwent non-ViV TAVI. This bicentric study included all patients who underwent aortic ViV procedure for surgical bioprosthetic aortic failure between 2013 and 2017. All patients who underwent TAVI were included in the analysis during the same period. ViV and non-ViV patients were matched with 12 ratio according to size, type of TAVI device, age (±5 years), sex, and STS score. Primary end point was hemodynamic performance including mean aortic gradient and aortic regurgitation at 1-year follow-up. A total of 132 patients were included, 49 in the ViV group and 83 in the non-ViV group. Mean age was 82.8 ± 5.9 years, 55.3% were female. Mean STS score was 5.2% ± 3.1%. Self-expandable valves were implanted in 78.8% of patients. At 1-year follow-up, aortic mean gradient was significantly higher in ViV group (18.1 ± 9.4 mm Hg vs 11.4 ± 5.4 mm Hg; p < 0.0001) and 17 (38.6%) patients had a mean aortic gradient ≥20 mm Hg vs 6 (7.8%) in the non-ViV group (p = 0.0001). Aortic regurgitation > grade 2 were similar in both groups (p = 0.71). In the ViV group, new pacemaker implantation was less frequent (p = 0.01) and coronary occlusions occurred only in ViV group (n = 2 [4.1%]). At 1-year follow-up, 3 patients (2.3%) died from cardiac cause, 1 (2.1%) in the ViV group vs 2 (2.4%) in the non-ViV group (p = 0.9). There was no stroke. In conclusion, compared with TAVI in native aortic stenosis, ViV appears as a safe and feasible strategy in patients with impaired bioprosthesis. As 1-year hemodynamic performances seem better in native TAVI procedure, long-term follow-up should be assessed to determinate the impact of residual stenosis on outcomes and durability.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estenose da Valva Aórtica / Reoperação / Bioprótese / Próteses Valvulares Cardíacas / Substituição da Valva Aórtica Transcateter Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estenose da Valva Aórtica / Reoperação / Bioprótese / Próteses Valvulares Cardíacas / Substituição da Valva Aórtica Transcateter Idioma: En Ano de publicação: 2019 Tipo de documento: Article